Fig. 7. Activation of α7nAChR augments IL-4-induced ARG1 expression relying on AKT1-FOXO1 signaling.

a Effect of GTS-21 on FOXO1/p-FOXO1, AKT1/p-AKT1, and ARG1 in IL-4 stimulated PR8-infected BMDM. The BMDM were treated with strategies listed in Fig. 4b. Experiments were repeated two times. b Analysis of nuclear p-FOXO1/FOXO1 ratio in GTS-21 treated IL-4-stimulated PR8-infected BMDM. The BMDM were treated using treating conditions in the Fig. 4b except IL-4 stimulation was given for 1 h instead of 18 h. The results were repeated two times. c, d The efficiency and effect of knockdown of Foxo1a on Arg1 expression in GTS-21 treated IL-4-stimulated PR8-infected BMDM. The BMDM were first given Scrambled ShRNA and Foxo1a ShRNA treatment and then received treatment using strategies listed in Fig. 4b. Data were pooled from three experiments. *P < 0.05, **P < 0.01, unpaired t test or One-way ANOVA. e Effect of deletion of Akt1 in myeloid cells on p-STAT6, p-AKT1, p-FOXO1, and ARG1 in α7nAChR-activated IL-4-stimulated PR8-infected BMDM. The Akt1^fl/fl and LysM^Cre Akt1^fl/fl bone marrow cells were isolated and BMDM cells were developed. The cells were treated following the procedure listed in Fig. 4b. The results were repeated at least two times.